Alpha Cognition ROE 2020-2024 | ACOG
Current and historical return on equity (ROE) values for Alpha Cognition (ACOG) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Alpha Cognition ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$-0.02B |
$-0.00B |
533.33% |
| 2024-03-31 |
$-0.02B |
$0.00B |
618.18% |
| 2023-12-31 |
$-0.01B |
$-0.01B |
560.00% |
| 2023-09-30 |
$-0.01B |
$-0.01B |
800.00% |
| 2023-06-30 |
$-0.01B |
$0.00B |
-2200.00% |
| 2023-03-31 |
$-0.01B |
$0.00B |
-733.33% |
| 2022-12-31 |
$-0.01B |
$-0.00B |
-400.00% |
| 2022-09-30 |
$-0.01B |
$0.00B |
-200.00% |
| 2022-06-30 |
$-0.01B |
$0.00B |
-247.62% |
| 2022-03-31 |
$-0.01B |
$0.01B |
-250.00% |
| 2021-12-31 |
$-0.02B |
$0.01B |
-950.00% |
| 2021-09-30 |
$-0.02B |
$0.00B |
7200.00% |
| 2021-06-30 |
$-0.02B |
$-0.00B |
3000.00% |
| 2021-03-31 |
$-0.02B |
$-0.00B |
6800.00% |
| 2020-12-31 |
$-0.01B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.035B |
$0.000B |
|
Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
|
